(Q38239310)

31 August 2017

title

Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature (English)

1 reference

31 August 2017

1 reference

3

Eugene Vlodavsky

1 reference

31 August 2017

2

Sergey Postovsky

1 reference

31 August 2017

5

Shlomi Constantini

1 reference

31 August 2017

4

Ayelet Eran

1 reference

31 August 2017

Oz Mordechai

1

1 reference

31 August 2017

Eynat Dotan

series ordinal

6

1 reference

31 August 2017

Emmanuela Cagnano

series ordinal

7

1 reference

31 August 2017

Myriam Weyl-Ben-Arush

series ordinal

8

1 reference

31 August 2017

language of work or name

1 reference

12 August 2014

1 reference

Pediatric Hematology and Oncology

31 August 2017

published in

1 reference

31 August 2017

volume

32

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

207-211

1 reference

Rhabdoid papillary meningioma: a clinicopathologic case series study

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

"Rhabdoid" meningioma: an aggressive variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Rhabdoid transformation of tumor cells in meningiomas: a histologic indication of increased proliferative activity: report of four cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

The Wnt signaling pathway in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Which drug, and when, for patients with BRAF-mutant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2014.936058

10.3109/08880018.2014.936058

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference